INTRODUCTION
Alzheimer's disease (AD) is the most common neurodegenerative disease, and the leading cause of progressive dementia. The principal neuropathological characteristics of AD are the two lesions first described by Alzheimer, neurofibrillary tangles and senile plaques, which are found at significantly higher frequency in the cortex and hippocampus of individuals with AD than in these brain regions in other aged individuals. 1 Senile plaques are composed of dystrophic neurites displayed around extra cellular deposits of 39-42-amino-acid-long amyloid-β (Aβ) peptides. Aβ is generated by sequential proteolytic processing of a large type I transmembrane protein, termed amyloid precursor protein (APP). It is becoming clear that changes in cholesterol homeostasis can markedly influence Aβ production, and studies in neuronal and non-neuronal cells have implicated membrane microdomains rich in cholesterol, termed lipid rafts, in amyloidogenic processing of APP.
In this article, we review recent developments in our knowledge of factors that affect amyloidogenic processing by influencing compartmentalization of APP and secretase activities, and discuss potential strategies and advantages of targeting APP processing in lipid rafts.
all transmembrane proteins-presenilin (PSN1 or PSN2), nicastrin, PEN2 and APH1. 4 In the first step of amyloidogenic processing, BACE1 cleaves APP to generate a secreted ectodomain (APPsβ) and a membrane-tethered C-terminal fragment (β-CTF). 2 Then, γ-secretase cleaves β-CTF within the trans membrane domain to release Aβ into the extracellular milieu and the APP intracellular domain into the cytoplasm. Alternatively, APP can be cleaved within the Aβ domain by α-secretase to generate a secreted ectodomain (APPsα) and a truncated C-terminal stub (α-CTF) that can also be cleaved by γ-secretase. This alternative,non amyloidogenic, processing pathway precludes intact Aβ formation, however, because α-secretase cleavage truncates the N-terminus of Aβ.
The amyloidogenic pathway initiated by BACE1 cleavage seems to be the predominant mode of APP metabolism in neurons, probably as a result of high levels of BACE1 expression. 5 In view of the fact that α-secretase and β-secretase cleavages of APP have opposing effects on Aβ generation, the elucidation of the signaling pathways and molecular events involved in the commitment of APP to these pathways has potential therapeutic value. Interestingly, the affinity of BACE1 for APP is relatively low, which indicates that APP is not its sole physiological substrate. Indeed, recent studies have identified additional BACE1 substrates including APP-like proteins (APLP1 and APLP2), β-galactoside α, 2,6-sialyl transferase, P-selectin glycoprotein ligand-1, low-density lipo protein receptor-related protein (LRP), β sub units of voltage-gated sodium channels, and neureguli n-1. [5] [6] [7] [8] [9] [10] [11] Similarly, γ-secretase can mediate sequence-independent cleavage of a wide range of type I transmembrane proteins that undergo ecto domain shedding, including Notch receptors and ligands, the netrin receptor DCC, the receptor tyrosine kinase erbB-4, and LRP, extending the physio logical role of PSN1 beyond the nervous system and AD patho genesis. 12 Strategies targeting BACE1 or γ-secretase activity will, therefore, have to consider-and incorporate rational means of avoiding-adverse consequences resulting from inhibition of the activities of the enzymes on these diverse substrates.
Secretases cleave APP in multiple subcellular compartments
Nascent APP is post-translationally modified by N-glycosylation, O-glycosylation, phosphoryla tion, and tyrosine sulfation en route to the plasma membrane in the secretory pathway ( Figure 1 , step 1). At steady state, the majority of APP is localized in the Golgi apparatus, trans-Golgi network (TGN), and post-TGN vesicles. APP trafficking in neurons has an extra layer of complexity, as APP is axonally transported via the fast anterograde transport machinery. As a consequence, the synaptically released Aβ pool is one documented source of amyloid deposits. 12, 13 In cultured cells, it is estimated that only about 10% of nascent APP molecules arrive at the plasma membrane. A fraction of APP is cleaved by α-secretases on arrival at the cell surface or during late steps in the transit to the surface, resulting in the shedding of APPsα ectodomain. 14 This mechanism is consistent with the known function of ADAM proteases in shedding ectodomain fragments of various trans membrane proteins, including tumor necrosis factor, the p75 tumor necrosis factor recep tor, Notch receptors, the Notch ligand Delta, transforming growth factor α, l-selectin, and the interleukin 6 receptor α subunit. Moreover, ADAM family metalloproteinases are type I transmembrane proteins that become active when their prodomain is removed by proteolytic processing as they traffic through the secretory pathway. Activation of protein kinase C increases APPsα secretion (a process referred to as 'regulated' α-secretase processing) by mechanisms that involve the formation and release of secretory vesicles from the TGN, thereby enhancing APP (and possibly α-secretase) trafficking to the cell surface. Unlike many cell surface receptors, fulllength APP does not reside at the cell surface for extended periods of time. It is estimated that roughly two-thirds of surface-bound APP is internalized within minutes of arriving at the plasma membrane ( Figure 1, step 2) . A 'YENPTY' internalization motif located at the C-terminal tail of APP is responsible for the molecule's efficient endocytosis. Following endocytosis, APP is trafficked to late endosomes and a fraction of endocytosed molecules are recycled to the cell surface ( Figure 1, step 3) . Studies that used pharmacological inhibitors have indicated that appreciable amounts of endocytosed APP can also undergo degradation within lysosomes. Data from analysis of transfected cell lines indicate that Aβ is mainly generated in the TGN as APP is trafficked through the secretory and recycling pathways. This conclusion is consistent with the subcellular sites at which BACE1 and γ-secretase predominantly reside in cultured cell lines.
BACE1 is synthesized as a preproenzyme, the prodomain of which is cleaved by furinlike protease as it is trafficked to the plasma membrane through the secretory pathway. BACE1 then cycles between the cell surface and endosomes, and at steady state the majority of BACE1 is found in the late-Golgi-TGN compartment and endosomes. 15 BACE1 is most active at acidic pH in vitro, which also implicates acidic organelles such as endosomes as major sites of BACE1 cleavage of APP. Indeed, there has been compelling early evidence to suggest that BACE1 cleaves wild-type APP during transit in the endocytic pathway. 16 By contrast, 'Swedish' double mutant (Lys670Asn-Met671Leu) APP, which is associated with familial early-onset AD, is more readily cleaved by BACE1 in the secretory pathway, as early as during the transit of nascent APP though the Golgi apparatus. 17 A significant amount of BACE1 is localized in lipid raft microdomains of cellular organelles (see below). The localization of γ-secretase has been a somewhat contro versial issue, because subunits of this enzyme have been found in multiple organelles including the endoplasmic reticulum (ER), ER-Golgi intermediate compartments, Golgi apparatus, endosomes, lysosomes, phagosomes, plasma membrane, and mitochondria. By combining fractionation with nonionic detergent extraction analysis, we found that γ-secretase components reside in cholesterol-rich and sphingolipid-rich detergent-resistant lipid raft microdomains of post-Golgi, TGN and endosome membranes (see below). 18 
LIPID RAFT LOCALIZATION OF BACE1 AND γ-SECRETASE

Lipid rafts
Specialized organelle membrane microdomains rich in cholesterol and sphingolipids, termed lipid rafts, participate in a variety of important biological functions. 19 Initially, lipid rafts were biochemically defined as detergent-insoluble membrane (DIM) domains that resisted extraction with certain nonionic detergents such as Triton ® X-100 (Union Carbide Chemicals & Plastics Technology Corporation, Danbury, CT) and Lubrol ® (Imperial Chemical Industries, London, UK) at 4 °C. 20 Most researchers now agree, however, that there are serious limitations in the use of detergents to study lipid raft localization of proteins in biological membranes, and other methods such as fluor escence visualization at nanoscale resolution must be used to corroborate biochemical results. 21 On the basis of a consensus between biophysicists, bio chemists and cell biologists, a working definition of lipid rafts was developed at the 2006 Keystone Symposium on Lipid Rafts and Cell Function: "membrane rafts are small (10-200 nm), heterogeneous, highly dynamic, sterol-and sphingolipid-enriched domains that compartmentalize cellular processes. Small rafts can sometimes be stabilized to form larger platforms through protein-protein and protein-lipid interactions". 22 Lateral segregation of cholesterol and sphingolipids is thought to initially occur in the Golgi, where nascent sphingolipids mature and are present on the plasma membrane, and in the membranes of the Golgi, TGN and endocytic compartments. Rafts are heterogeneous in size and lifetime, and it has been suggested that they act as ordered platforms, which float around in the liquid-disordered matrix of the cellular membranes and represent versatile devices for compartmentalization of membrane-associated signaling processes. 19, 23 Association of β-secretase with lipid rafts Mounting evidence suggests that lipid rafts might be the principal membrane domains in which amyloidogenic processing of APP occurs. BACE1 undergoes S-palmitoylation, a post-translational modification responsible for targeting a variety of cytosolic and trans membrane proteins to lipid rafts. 24 Indeed, biochemical fractionation and antibody co-patching methods reveal that a significant fraction of BACE1 is found in lipid rafts, and targeting the BACE1 lumenal domain to lipid rafts via the addition of a glycophosphatidylinositol anchor increases APP processing at the β-cleavage site. [25] [26] [27] Elegant studies by Ehehalt and colleagues showed antibody-mediated co-patching of cell surface APP and BACE1, as well as amyloidogenic processing of APP, in raft microdomains. 28 Interestingly, however, Abad-Rodriguez et al. recently reported that displacement of BACE1 from raft domains by moderate reduction of cholesterol promoted membrane proximity of BACE1 and APP in nonraft domains and increased β-cleavage of APP. 29 Unlike BACE1, α-secretases have not been linked to raft micro domains on the basis of cholesterol depletion and loading studies. 28 
Association of γ-secretase with lipid rafts
Each of the four core subunits of the γ-secretase complex (PSN1-derived N-terminal and C-terminal fragments, nicastrin, APH1, and PEN2) is localized in DIM fractions enriched in the lipid raft markers flotillin-2 and prion protein ( Figure  2 ). 18 The association of γ-secretase components with DIM domains is sensitive to acute cholesterol depletion with the cholesterolsequestering agent methyl-β-cyclodextrin, fulfilling one of the stringent criteria for lipid raft localization. The paucity of γ-secretase at the plasma membrane has made cell surface co-patching studies un successful in visualizing membrane raft localization of endogenous γ-secretase. Nevertheless, detailed bio chemical fractionation studies, including magnetic immunoisolation, indicate that the γ-secretase complex co-resides in lipid raft microdomains with APP CTFs and SNARE proteins such as VAMP-4 (in the TGN), syntaxin-6 (TGN and vesicles) and syntaxin-13 (early endosomes). 18 These studies strongly implicate lipid raft microdomains of intracellular organelles as the preferred sites of γ-secretase processing of APP CTFs. Interestingly, the cell-surface raftassociated protein SNAP-23 does not co-reside with mature components of the γ-secretase complex, raising the possibility that the relatively small amount of active γ-secretase complex present at the cell surface could be residing in nonraft membrane domains. 18 Such spatially distinct localization of the γ-secretase complex probably allows intramembranous processing of diverse substrates. Indeed, our recent studies indicate that APP CTFs in adult brain and cultured cells preferentially accumulate in raft microdomains (Figure 2 ), whereas several other substrates, such as CTFs derived from Notch1, Jagged2, N-cadherin and DCC, remain in nonraft membranes. 30 Taken together, these findings are consistent with the prediction that γ-secretase cleavage of APP occurs in lipid rafts (Figure 3 ). Further investigations are needed to clarify the mechanisms that regulate γ-secretase distribution between raft and nonraft micro domains.
TARGETING APP PROCESSING IN LIPID RAFTS
Therapeutic strategies aimed at modulation of lipids have been proposed for the treatment of several diseases, including cancer, cardiovascular disease, obesity, metabolic dis orders, infectious diseases, inflammation, and Alzheimer's disease. 31 The organization and maintenance of lipid rafts can potentially be modulated by controlling the cellular levels of cholesterol and sphingolipids. The targeting of amyloidogenic processing in lipid rafts is a relatively un explored area in Alzheimer's disease therapeutics. Nevertheless, there is a wealth of information implicating cholesterol levels in AD pathogenesis, and cholesterol has been considered to be major candidate for treatments targeting amyloidogenic processing of APP in lipid rafts.
Cholesterol and amyloid-β production
Cholesterol has attracted particular interest in the context of AD pathogenesis in recent years. Levels of total cholesterol and LDL cholesterol in serum have been found to correlate with Aβ load in the brains of patients with AD. 32 CHENG ET AL. JULY 2007 VOL 3 NO 7 www.nature.com/clinicalpractice/neuro Epidemiological evidence suggests that elevated cholesterol levels during midlife increase the risk of developing AD. 33 In retrospective studies, patients treated with statins (inhibitors of hydroxy methylglutaryl-CoA reductase, the rate-limiting enzyme in cholesterol synthesis) The lysates were then subjected to flotation sucrose density gradient centrifugation to separate cholesterol-rich detergent-insoluble membranes (enriched in lipid raft markers) from detergentsoluble proteins. 30 An equal volume of each fraction was analyzed by Western blotting with antibodies against the amyloid precursor protein (APP) C-terminus, β-site APP-cleaving enzyme 1 (BACE1), presenilin 1 (PSN1) and nicastrin. (B) A model, inferred from the data shown in (A), depicting compartmentalization of APP C-terminal fragments and secretases in lipid rafts. Full-length APP is predominantly localized in nonraft regions of membranes, whereas APP C-terminal fragments are highly abundant in lipid rafts. BACE1 seems to be distributed evenly between raft and nonraft domains, whereas γ-secretase preferentially associates with lipid rafts. α-Secretases are excluded from lipid rafts, and are not shown here for the sake of clarity. Abbreviations: APP CTF, amyloid precursor protein C-terminal fragments; APP FL, full-length amyloid precursor protein; BACE1, β-site APP-cleaving enzyme 1; PSN1 NTF, presenilin 1 N-terminal fragment. Figure 2A . A subset of APP FL becomes associated with lipid rafts, and is sequentially processed by β-site APP-cleaving enzyme 1 (BACE1) and γ-secretase. The models differ with respect to the microdomain localization of BACE1 cleavage, which has not been fully resolved by cholesterol depletion studies. 28, 29, 37 Abbreviations: APP, amyloid precursor protein; Aβ, amyloid-β; APPsβ, BACE1-generated amyloid precursor protein ectodomain; BACE1, β-site APP-cleaving enzyme 1; β-CTF; amyloid precursor protein β-C-terminal fragment.
to reduce their cholesterol levels showed significantly reduced prevalence and incidence of AD. 34, 35 In agreement with these results, elevated dietary cholesterol uptake has been found to increase amyloid plaque formation in rabbits. 36 Furthermore, cholesterol loading and depletion studies in cultured cells and in transgenic mouse models of AD have found a correlation between cholesterol levels and the efficiency of Aβ production and deposition. [37] [38] [39] [40] For example, depletion of cholesterol by 70% (measured by equilibrium labeling of the cholesterol pool with 3 H cholesterol for 16 h) in cultured hippocampal neurons, through treatment with a combination of the lipophilic statin lovastatin and the cholesterol-extracting agent methyl-β-cyclodextrin, markedly lowered Aβ production. 37 In guinea pigs, as well as in an APP-PSN1 double-transgenic mouse model, treatment with cholesterol-lowering drugs markedly reduced Aβ deposition, demonstrating a positive association between plasma cholesterol levels and cerebral Aβ load. 38, 40 Statins are clinically safe drugs that pass through the blood-brain barrier, so they could potentially be used as an effective means of reducing Aβ burden. Recently, however, the beneficial effects of statins with respect to the incidence of AD and cognitive decline in patients with AD have been challenged. [41] [42] [43] Furthermore, it has been suggested that the primary action of statins in humans with AD might be to reduce inflammation attributable to microglial activation, rather than to decrease Aβ load. 44 Decisions regarding the clinical use of statins as a therapy for AD pathogenesis are, therefore, likely to depend on the outcomes of additional larger clinical trials.
Certain aspects of cholesterol metabolism seem to regulate Aβ generation via direct effects on the amyloidogenic processing of APP by BACE1 and γ-secretase. This outcome is expected, given the association of BACE1, γ-secretase and APP CTFs with lipid rafts. In addition to modulating BACE1 and γ-secretase processing, lowering of cholesterol levels leads to marked elevation of non amyloidogenic processing of APP by increasing α-secretase expression and activity, and through other mechanisms including accumulation of APP at the cell surface and altered membrane fluidity. 45 The results of a recent study have, however, raised concerns about the pursuit of a therapeutic strategy that uses drugs to lower cholesterol. In contrast to the drastic decrease in cholesterol levels achieved in many studies, Abad-Rodriguez et al. showed that moderate reduction (<25% loss) of membrane cholesterol in cultured hippocampal neurons paradoxically increased Aβ production by promoting β-secretase cleavage of APP. 29 This investigation found that moderate loss of cholesterol in hippocampal neurons facilitated colocalization of APP and BACE1 by displacing BACE1 from lipid rafts. They did, however, show that a greater than 35% loss of membrane cholesterol (quantified using enzymatic oxidation of cholesterol) led to a marked decrease in Aβ production, confirming the earlier data on cholesterol depletion and APP processing. This study therefore indicates that the extent of cholesterol loss is a critical factor that determines the level of Aβ production.
Further important confounders of the proper interpretation of statin studies of Aβ production are the pleiotropic effects of cholesterol depletion on Golgi morphology and vesicular trafficking; these effects are expected consequences of changes in both membrane fluidity and curvature. 46, 47 Furthermore, lovastatin has been shown to decrease cholesterol levels in the exofacial membrane leaflet and to reduce membrane bulk fluidity. 48 The precise interplay between cholesterol levels, APP trafficking and processing at the subcellular level might, therefore, be much more complicated than was previously understood. In addition to total cholesterol level, sub cellular distribution and transport of cholesterol have also been found to be critical for APP metabolism. Inhibition of intra cellular cholesterol transport from late endocytic organelles to the endoplasmic reticulum by class 2 amphiphiles, such as U18666A, causes dose-dependent reduction in levels of both secreted and cellular Aβ in cultured neurons and neuroblastoma cells. 49 Overexpression of ATP-binding cassette transporter A1, which mediates cholesterol efflux, decreases Aβ production by reducing BACE1 and γ-secretase cleavage of APP. 50 In other studies, a correlation between cellular cholesteryl ester levels and Aβ production has been found. 51 A more recent study carefully assessed the effects of statins, which lower the levels of cholesterol and nonsterol iso prenoids such as farnesyl pyrophosphate and geranylgeranyl pyrophosphate, and found strong evidence CHENG ET AL. JULY 2007 VOL 3 NO 7 www.nature.com/clinicalpractice/neuro that lowering cellular isoprenoid levels increased the intracellular pool of APP metabolites and Aβ. Addition of mevalonate at a low level was sufficient to rescue statin-induced blockade of isoprenoid synthesis and prevented such an increase in intracellular Aβ levels. These results raise the intriguing possibility that cholesterol and isoprenoid levels have independent effects on APP metabolism and Aβ production, highlighting the importance of exercising caution when interpreting experiments in which statins were used as a means of lowering cholesterol levels in the absence of exogenous mevalonate. 52 As another major component of membrane raft domains, sphingolipids are also involved in the regulation of APP processing. Lowering sphingolipid levels, either by inhibiting serine palmitoyltransferase, which is involved in the early step of sphingolipid biosynthesis, or by mutating one of the serine palmitoyl transferase enzyme subunits, elevates α-secretase cleavage. 53 In addition, secretion of Aβ42, but not that of Aβ40, is markedly elevated under these conditions, suggesting additional modulation of γ-secretase cleavage. Recently, Grimm and colleagues reported an intriguing link between APP processing and the regulation of cholesterol and sphingomyelin meta bolism. Aβ42 directly decreased sphingomyelin levels by activating neutral sphingomyelinases, whereas Aβ40 reduced de novo cholesterol synthesis by inhibiting hydroxymethylglutaryl-CoA reductase activity. Expression of familial early-onset AD-linked mutant forms of PSN1 in fibroblasts increases cholesterol levels and reduces sphingomyelin levels, providing strong support for a physiological role for endogenous Aβ in regulating cholesterol and sphingomyelin metabolism. Nevertheless, the possibility that metabolites derived from γ-secretase cleavage of other type I membrane receptors might also influence lipid homeostasis has not been formally ruled out. 54 Displacing BACE1, γ-secretase or APP from lipid rafts
The reason why some proteins preferentially associate with lipid rafts is not completely understood, but certain lipid modifications have been found to be critical for such asso ciations. One modification, attachment of a glycophosphatidylinositol group, is found on proteins that are located on the extracellular face of the plasma membrane. Other modifications, such as N-myristoylation and S-palmitoyla tion, are found on transmembrane proteins and cytosolic proteins that associate with the cytoplasmic face of intracellular membranes. The targeting of proteins to lipid rafts through N-myristoylation and S-palmitoylation relies on the ability of the saturated fatty acid to fit well in an ordered lipid environment, rather than on the hydrophobic property of the lipids. 55 In addition to lipid attachment, hydrophobic transmembrane domain residues in contact with the exoplasmic leaflet of the membrane have been implicated in raft association of proteins. 56 Protein-protein interactions also facilitate raft targeting of certain proteins, such as in the case of raft localization of glutamate receptor-interacting protein 2 (GRIP2) through interaction with the C-terminus of the raft-resident transmembrane protein ephrin B1. 57 As described above, BACE1 undergoes S-palmitoylation at three cysteine residues within its transmembrane domain and cytosolic tail. 24 Mass spectrometry analysis of BACE1 purified from transfected HEK293 cells revealed that the extent of S-palmitoylation was marked ly reduced by treatment with the cholesterol inhibitor lovastatin. 58 Whether this decrease in S-palmitoylation is attributable to altered intracellular trafficking of BACE1 or is a consequence of pleiotropic effects of statins on cellular physiology has not been assessed. Nevertheless, it is possible to develop strategies that would compromise S-palmitoylation of BACE1, the rationale being that exclusion of BACE1 from lipid rafts might lower Aβ production. Overexpression of palmitoylationdeficient BACE1, however, resulted in an increase in Aβ11-40 peptide levels with no significant change in Aβ1-40 levels. 24 Displacing BACE1 from raft domains might, therefore, promote BACE1 processing of APP by removing the spatial barrier that separates raft-localized BACE1 from non-raft-localized APP. This interpretation is entirely consistent with the enhanced Aβ production observed in studies with moderate cholesterol extraction, and with findings in mice heterozygous for the cholesterol-synthesizing enzyme seladin-1. 29, 59 As mentioned above, γ-secretase and APP CTFs co-reside in raft microdomains of late endosomes, the TGN, and TGN-derived vesicles. 30 In theory, displacing either γ-secretase or APP CTFs from raft domains should prove effective in reducing Aβ production, by compromising the spatial proximity of the enzyme and the substrate. The mechanisms regulating raft association of γ-secretase complex are not, however, fully understood. Similarly, the signals within the trans membrane domain or cytosolic tail of APP that promote preferential segregation of APP CTFs into lipid rafts following ectodomain shedding of APP remain to be identified. The available data indicate that APP association with lipid rafts is enhanced during endocytic trafficking. 28 It remains to be determined whether proteins such as Mint, Fe65, LRP and GGA, which modulate APP trafficking and processing and Aβ production, affect raft versus nonraft distribution of APP. Displacement of fulllength APP from lipid rafts might inhibit the amyloidogenic pathway initiated by BACE1 by shifting of APP ectodomain shedding to the nonamyloidogenic pathway mediated by α-secretases in nonraft domains. Finally, it might be possible to modify BACE1 or γ-secretase inhibitors to increase their affinity for cholesterol-containing membrane domains in an attempt to selectively target amyloidogenic processing of APP in lipid rafts. In view of the fact that a number of γ-secretase substrates are spatially segregated in nonraft domains, 30 selective inhibition of raft-localized γ-secretase might obviate the potential side effects of complete inhibition of this enzyme.
CONCLUSIONS
Numerous recent investigations have focused on the molecular mechanisms underlying the pathogenesis of AD, and the development of novel therapeutic strategies that selectively inhibit Aβ production. Multiple lines of evidence suggest that amyloidogenic processing of APP is associated with membrane raft microdomains. Targeting APP processing in lipid rafts, as opposed to the standard strategy of inhibiting BACE1 and γ-secretase by blocking their active sites, has the potential to selectively reduce Aβ burden without the adverse effects associated with overall inhibition of the actions that these enzymes exert on a variety of other substrates. Identification of the elusive mechanisms responsible for raft localization of APP CTFs and γ-secretase could provide a strong impetus for the development of novel thera peutics based on the targeting of APP processing in lipid rafts.
KEY POINTS
■
Cholesterol has been an important focus of research into Alzheimer's disease, but controversy has emerged regarding the therapeutic value of lowering cholesterol as a protective measure against this disease ■ Certain aspects of cholesterol metabolism regulate amyloid-β production through direct modulation of amyloid precursor protein (APP) processing by secretases ■ β-Site APP cleaving enzyme 1, γ-secretase and APP C-terminal fragments are localized in lipid rafts, which are membrane microdomains rich in cholesterol and sphingolipids ■ Amyloidogenic processing of APP occurs in lipid raft domains, and experimental manipulations that disturb the integrity of lipid rafts affect amyloid-β production ■ Compartmentalization of APP C-terminal fragments and secretases offers unique opportunities to selectively target APP processing
